Pfizer Consumer Chief Sees Chronic Conditions In OTC Future
This article was originally published in The Pink Sheet Daily
The Pfizer exec's switch expectations align with FDA drug center chief Janet Woodcock's recent comments that nonprescription treatments for conditions including high cholesterol, hypertension, diabetes and obesity would benefit the public health.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.